

## COMMUNICATION

[View Article Online](#)  
[View Journal](#)

Cite this: DOI: 10.1039/d5cb00282f

Received 31st October 2025,  
Accepted 27th November 2025

DOI: 10.1039/d5cb00282f

[rsc.li/rsc-chembio](https://rsc.li/rsc-chembio)Late-stage peptide modification with  
salicylaldehyde tag enhances affinity  
for nuclear factor-kappa B essential modulatorMattia Mason,<sup>a</sup> Kaliroi Pegini,<sup>b</sup> Federico Uggeri,<sup>a</sup> Diego Rondelli,<sup>bc</sup>  
Sara Sattin,<sup>a</sup> Luca Pignataro,<sup>a</sup> Sara Pellegrino,<sup>b</sup> Laura Belvisi,<sup>a</sup>  
Edoardo Scarpa,<sup>bc</sup> Raffaella Bucci<sup>\*b</sup> and Alberto Dal Corso<sup>\*a</sup>

The late-stage peptide functionalization with salicylaldehyde (SA) tags is described here as a versatile design of potential Lys-engaging, reversible-covalent ligands. This approach was applied to a known binder for NEMO, a protein involved in the activation of the pro-inflammatory transcription factor NFκB. Fluorescence anisotropy screening led to the identification of SA-tagged peptides with higher affinity than the wild-type sequence.

## Introduction

In recent years, growing attention has been devoted to the identification of peptide and peptidomimetic ligands capable of selectively targeting proteins of interest,<sup>1</sup> particularly those forming covalent bonds with their targets.<sup>2</sup> This emerging class of covalent peptide binders offers unique opportunities for designing potent and durable modulators of protein functions. Salicylaldehyde (SA) derivatives have emerged as powerful amine-engaging units and, stimulated by the high frequency of Lys residues in the proteome,<sup>3</sup> they have been incorporated in various small molecule drugs,<sup>4</sup> glycomimetic<sup>5</sup> and peptide<sup>6</sup> ligands.

In the latter context, considering that protein–peptide binding interactions typically span a wide interface area, the precise insertion of the SA tag at suitable peptide positions could be crucial to covalently engage a specific Lys(ε-NH<sub>2</sub>) group of the target protein. Ideally, this additional covalent interaction could synergize with the original non-covalent forces, resulting in a highly stable ligand–protein complex.

With this aim, we recently reported on the synthesis of non-coded amino acids, substituting the homoserine side chain with a SA tag. These new scaffolds, endowed with suitable

protecting groups, could be inserted in primary sequences during peptide synthesis.<sup>7</sup> Unfortunately, these modified amino acids could be obtained only with long and inefficient multistep synthetic sequences, which strongly limit their use as building blocks for peptide production. For this reason, we looked at more practical and versatile design of SA-tagged peptides.

“Click” chemistry approaches, such as the copper-catalysed azide–alkyne cycloaddition (CuAAC), offer unique opportunities to connect two highly functionalized molecules in an efficient and chemoselective way.<sup>8</sup> In particular, CuAAC proved a robust approach to connect the azido group in biomolecules (*i.e.* nucleic acids<sup>9</sup> and peptides N and C-termini<sup>6</sup>) to alkyne-bearing SA derivatives, devoid of protecting groups on the aldehyde and phenol units.

Propargylglycine (Pra) is a non-coded amino acid featuring a terminal alkyne group on its side chain: its N-Fmoc protected version is commercially available in both enantiomeric forms, enabling the insertion of alkyne units in peptide sequences through solid phase peptide synthesis (SPPS).

Inspired by the high versatility of the Pra amino acid, we designed a practical strategy for the preparation of potential Lys-engaging peptides (Fig. 1), consisting in the Pra insertion within the peptide sequence and subsequent installation of the SA tag through CuAAC.

A known peptide–protein interaction was selected as a case study to verify the feasibility of our approach, demonstrating that the generation of a panel of SA-tagged peptides and their screening against the protein of interest can lead to hit compounds with enhanced binding affinity compared to the wild-type peptide sequence.


## Results and discussion

Two SA derivatives bearing an azido group were designed and prepared as highlighted in Scheme 1. In particular, the azido group was connected to the aromatic ring through either a


<sup>a</sup> Università degli Studi di Milano, Dipartimento di Chimica, 20133 Milano, Italy.  
E-mail: [alberto.dalcorso@unimi.it](mailto:alberto.dalcorso@unimi.it)

<sup>b</sup> Università degli Studi di Milano, Dipartimento di Scienze Farmaceutiche, 20133 Milano, Italy. E-mail: [raffaella.bucci@unimi.it](mailto:raffaella.bucci@unimi.it)

<sup>c</sup> Istituto Nazionale di Genetica Molecolare (INGM), 20122 Milano, Italy



**Fig. 1** Design of potential reversible-covalent peptide binders through tailored insertion of a propargylglycine residue (Pra) at suitable positions of the peptide original sequence, followed by installation of the salicylaldehyde (SA) tag through CuAAC. Ideally, the resulting SA-tagged peptide form an imine adduct with the amino group of a specific Lys residue close to the peptide binding site, stabilizing the peptide–protein complex.



**Scheme 1** Synthesis of SA-azide derivatives bearing either a phenol ether (**SA<sub>O</sub>**) or a methylene (**SA<sub>C</sub>**) spacer. Reagents and conditions: (a) [1] NaN<sub>3</sub>, THF, H<sub>2</sub>O, 0 °C to 50 °C, overnight; [2] TsCl, Et<sub>3</sub>N, CH<sub>2</sub>Cl<sub>2</sub>, 0 °C to r.t., overnight; (b) hydroquinone, K<sub>2</sub>CO<sub>3</sub>, Bu<sub>4</sub>NI, DMF, 80 °C, overnight; (c) paraformaldehyde, anhydrous MgCl<sub>2</sub>, dry Et<sub>3</sub>N, dry THF, 70 °C, 4 h; (d) imidazole-1-sulfonylazide-HSO<sub>4</sub><sup>−</sup>, NaHCO<sub>3</sub>, CuSO<sub>4</sub>·5H<sub>2</sub>O, MeOH, r.t., overnight.

phenol ether bond (**SA<sub>O</sub>**) or a short alkyl chain (**SA<sub>C</sub>**). **SA<sub>O</sub>** was prepared starting from 2-bromoethanol, which was transformed into the corresponding azide through an S<sub>N</sub>2 reaction and then treated with tosyl chloride, to give compound **1** in good yields. Following the same strategy reported by our group in 2021,<sup>10</sup> the tosyl ester was reacted with hydroquinone, to give ether **2**, and then subjected to a regioselective phenol *ortho*-formylation under the Skattebøl conditions. The second SA-azide unit (**SA<sub>C</sub>**) was prepared in only two synthetic steps, starting from commercially available tyramine. Following a published protocol,<sup>11</sup> the diazo-transfer reagent imidazole-1-sulfonylazide was prepared as a hydrogen sulphate salt, which

can be handled safely as a solid. This reagent converted tyramine into the corresponding azide **3** in excellent yield (94%). Finally, a phenol *ortho*-selective formylation led to the desired SA-azide derivative **SA<sub>C</sub>**. The detailed reaction procedures and analytical data are included in the SI.

To compare the reactivity of aldehydes **SA<sub>O</sub>** and **SA<sub>C</sub>** towards imine bond formation in aqueous solution, a nuclear magnetic resonance (NMR) experiment was performed, following published protocols.<sup>9,12</sup> Stock solutions of the SA-azide derivatives in DMSO-*d*<sub>6</sub> were diluted in phosphate buffer prepared in deuterium oxide (pH 7.4), and <sup>1</sup>H-NMR spectra were recorded both in the presence or absence of *N*<sub>ε</sub>-acetyl-lysine in 10-fold molar excess. As shown in Fig. S1 (SI), after 1 h incubation at room temperature, the presence of Lys in the mixture led to approx. 33% conversion of both aldehydes into the corresponding imines, indicating that the **SA<sub>O</sub>** and **SA<sub>C</sub>** are similarly reactive toward the Lys(ε-NH<sub>2</sub>) group.

The synthesized SA-azide derivatives were then installed in a model peptide binder. As a case study, we selected the protein–protein interaction (PPI) between the Ser/Thr-specific IκB kinase (IKK) and the nuclear factor-kappa B essential modulator (NEMO), which represents an important step in the activation of the pro-inflammatory transcription factor NFκB. Given this relevant role in the inflammatory signalling cascade, the IKK:NEMO PPI has been identified as an attractive clinical target and as subject of various peptide discovery campaigns.<sup>13</sup> The TALDWSWLQTE sequence of IKKβ proved a fundamental player of this PPI, leading to the identification of this 11-mer fragment as NEMO-binding peptide (NBP).<sup>14</sup> Interestingly, while NBP does not include Lys residues, the crystal structure of the NEMO-IKKβ complex revealed the presence of three Lys(ε-NH<sub>2</sub>) groups in NEMO, proximal to the interface with the 11-mer IKKβ fragment (Fig. 2).<sup>15</sup>

The analysis of Lys(ε-NH<sub>3</sub><sup>+</sup>) pK<sub>a</sub>, performed with the Rosetta software, led to pK<sub>a</sub> values of 11.4, 9.9 and 10.4 for NEMO K90, K96 and K102, respectively (shown in Fig. 2), indicating that K96 may be the most nucleophilic site of the series. This residue, together with K90, is particularly close to IKKβ NBD (the measured distances vary from approximately 7 and 11 Å, all details are shown in Fig. S2), lying in the surrounding of the peptide N-terminus. In this region, the short distance between the amide proton in the backbone of IKKβ F734 and the side chain of NEMO E89 indicates the formation of an intermolecular H-bond (Fig. S2). In addition, F734 shows hydrophobic interactions with NEMO L93. As these non-covalent forces conceivably play a significant role in the complex stabilization, we included the F734 residues as the peptides' N-termini, resulting in the final FTALDWSWLQTE sequence. Finally, moving towards the peptide C-terminus, the hydrophobic features and the peculiar conformation of the WSWL fragment appear crucial for the PPI stabilization. In light of these observations, the three N-terminal residues of the FTALDWSWLQTE sequence (*i.e.*, IKKβ residues F734, T735 and A736) were identified as potential anchoring points for the SA tag, ideally aimed at the engagement of either K90 or K96, without disrupting the relevant non-covalent interactions of the wild-type sequence (Fig. 3A).






Fig. 2 Crystal structure of the NEMO-IKK $\beta$  complex (PDB: 3BRV). IKK $\beta$  residues 727–743 (NEMO binding domain, NBD, chain A) are shown in green stick representation, with different colours for F734 (purple), T735 (magenta), A736 (yellow). The single chains of homodimeric NEMO are shown with surface representation, while NEMO E89 and Lys residues close to the interface with IKK $\beta$  NBD (K90 in NEMO chain D, K96 and 102 in chain B) are shown in stick representation. The figure was obtained from the published PDB and originally-edited with Schrödinger Maestro graphical interface (Schrödinger release 2025-3). pK<sub>a</sub> values of Lys(ε-NH<sub>3</sub><sup>+</sup>) groups, calculated with Rosetta, are indicated in brackets (red). Measured distances between NEMO Lys residues and IKK $\beta$  F734, T735, and A736 are shown in Fig. S2.

As a final feature of the target peptides, a  $\beta$ -alanine unit was located at the N-termini as a spacer for the peptides labelling with fluorescein isothiocyanate (FITC), an essential dye for fluorescent anisotropy (FA) studies.

The designed peptide sequences are represented in Fig. 3A, and include the wild-type peptide 4 and its three analogues with single-point mutations at N-terminal F, T and A residues with Pra (peptides 5, 6 and 7, respectively). These peptides were prepared by automated, microwave-assisted SPPS, an efficient technique for peptide production within a short period of time.<sup>16</sup> Following the HPLC purification of Pra-bearing peptides 5–7, the alkyne group of each compound was easily connected to either SA<sub>O</sub> or SA<sub>C</sub> azides through CuAAC, to give the corresponding SA-tagged peptides. All compounds were purified by HPLC and the chromatograms of crude reaction mixtures (see Fig. S3 in the SI) indicated quantitative conversions of all alkynes 5–7 into the corresponding triazoles. Isolated products were characterized by LC-MS, as detailed in the SI.

Following a published protocol,<sup>13b</sup> FA assays were performed using recombinant NEMO, tagged with glutathione-S-transferase (GST) and produced by a commercial supplier. The resulting peptide (compound 4 in Fig. 3A) showed low affinity for GST-NEMO ( $K_d > 25 \mu\text{M}$ , as no FA saturation was observed at high protein concentrations, see Fig. 3B), in line with data reported elsewhere for NBP.<sup>17</sup> At this stage, the six SA derivatives were screened in parallel against GST-NEMO in FA binding studies, and the results are shown in Fig. 3C. Among these compounds, 6-SA<sub>C</sub>, 7-SA<sub>C</sub> and 7-SA<sub>O</sub> showed the best binding performances, with saturation of FA values over 1  $\mu\text{M}$  concentration. Of note, we observed no significant differences among FA data recorded at




Fig. 3 (A) design of modified NEMO-binding peptides with the Pra residue inserted in place of N-terminal phenylalanine (F), threonine (T) or alanine (A) residues. Peptides 4–7 were equipped with a  $\beta$ -alanine ( $\beta$ A) spacer and fluorescein isothiocyanate (FITC) for FA binding assays. (B)–(D) FA data of synthesized peptides and their SA derivatives, incubated in PBS (pH 7.4) at 125 nM concentration with GST-NEMO at variable concentrations. \*The dotted line marks the GST-NEMO concentration of 125 nM, equimolar to the ligand in solution:  $K_D$  values similar or lower to this threshold are named herein as "apparent  $K_D$ ". (E) FA data of alkyne 6, 6-SA<sub>C</sub>, and the aldehyde-free analogue 6-3, incubated at 125 nM concentration with 1 and 0.1  $\mu\text{M}$  GST-NEMO.

various incubation times. For homogeneity, all data described here were obtained upon 30 minutes of incubation.

This screening prompted us to investigate the affinity of these hit compounds in comparison with their cognate alkyne precursors 6 and 7. The results of this experiment, performed in duplicate, are shown in Fig. 3D, unveiling a remarkably higher binding affinity of SA derivatives compared to the original Pra-modified peptides. Compound 6-SA<sub>C</sub> proved particularly promising, with an apparent  $K_d$  value of  $60 \pm 9 \text{ nM}$ . Finally, to verify the impact of the peculiar SA reactivity on the observed affinity, the alkyne group of peptide 6 was reacted with the azide unit of phenol 3, devoid of the formyl group. This led to an analogue of lead compound 6-SA<sub>C</sub> (named 6-3), with suppressed aminophilic behaviour. In a dedicated FA study, including peptide 6 and its derivatives 6-SA<sub>C</sub> and 6-3, the absence of the aldehyde proved detrimental for the adhesion properties of the peptide (Fig. 3E), thus confirming the importance of the SA reactivity for the peptide binding potency.

These FA data confirmed our hypothesis that the tailored insertion of the SA tag into a peptide binder can significantly increase its affinity for the protein target. With the present data, we can only presume that the enhanced affinity is due to the formation of an intermolecular imine adduct, as only in-depth





investigations through mass spectrometry or X-ray crystallography can ultimately prove this interaction.

At this stage, we focused on the characterization of our peptide's solubility properties, as the renowned solubility issues of peptides can hinder the follow-up investigations, both in cellular and biochemical assays *in vitro*. For this purpose, the aldehyde-bearing peptide **6-SA<sub>C</sub>** and its alkyne precursor (**6**) were dissolved in DMSO at various concentrations and then diluted 1 : 100 in PBS, to give samples at 5  $\mu$ M, 125 nM, and 10 nM in PBS (+1% DMSO). These samples were then subjected to dynamic light scattering (DLS) studies and the results are shown in Fig. S4 (SI). In particular, while peptides formed large and stable aggregates at 5  $\mu$ M concentrations, the 125 and 10 nM solutions resulted in a rapid decay of correlograms and a shift of size distributions toward small aggregates. These data indicate the 125 nM concentration (*i.e.*, the value adopted in FA studies) as a solubility limit for these species in solution. As a consequence, future studies involving higher sample concentrations will require structural optimization or a fine tuning of sample preparation protocols (*e.g.*, screening of buffers, surfactants, *etc.*).

## Conclusions

We have described herein a protocol for a general functionalization of peptide ligands with the SA tag, *i.e.*, a well-known amine-engaging electrophile. Ideally, our design aims at the reversible-covalent engagement of amino groups in proteins and the generation of lead peptides with ultra-high affinity. The preliminary insertion of the Pra residue in a restricted area of the peptide's primary sequence was guided by visual inspection of crystal structures available in the PDB, but more systematic approaches are also feasible. The late-stage peptide modification with SA-azide fragments (**SA<sub>O</sub>** and **SA<sub>C</sub>**) through CuAAC avoids the use of protecting groups and generates the final products with high efficiency (see chromatograms in Fig. S3), ideally allowing the application of this strategy in highly diluted peptide solutions (*e.g.*, in combinatorial libraries).

In our NEMO-binding peptides, the increased binding affinity observed for our SA-tagged ligands compared to the control compounds supports the feasibility of SA-tagged "anti-inflammatory peptides". However, the self-assembly tendency of these peptides, revealed by DLS, may limit their efficient cellular uptake and the interaction with the biological target. Therefore, future biological evaluation will consider peptide incorporation in copolymers or the installation of cell-penetrating sequences.

Considering the high abundance of Lys residues in the proteome and their preferential expression on protein surfaces, we believe that the SA insertion into peptide ligands holds promises for the development of synthetic ligands with unprecedented affinities and prolonged residence time on the target.

## Author contributions

Conceptualization, supervision and writing: RB, ADC; methodology, investigation and data curation: MM, KP, FU, LB, DR,

ES; resources: SS, LP, SP; funding acquisition: RB, ADC, ES, SS, LB.

## Conflicts of interest

There are no conflicts to declare.

## Data availability

The data supporting this article have been included as part of the supplementary information (SI). Supplementary information is available. See DOI: <https://doi.org/10.1039/d5cb00282f>.

## Acknowledgements

We thank M. Rossoni for its assistance with the computational analysis. The Università degli Studi di Milano is gratefully acknowledged for the PhD fellowship (to MM) and for financial contributions (to RB and ADC, My First SEED Grant 2023 "RECIPE"). E.S. acknowledges Fondazione Cariplo (grant number 2022-0438) for financial support. SS was funded by the European Union – Next Generation EU, Mission 4, Component 2, CUP B93D21010860004.

## References

- (a) L. Lombardi, V. Del Genio, F. Albericio and D. R. Williams, *Chem. Rev.*, 2025, **125**, 7099; (b) D. Petrov, L. Plais, K. Schira, J. Cai, M. Keller, A. Lessing, G. Bassi, S. Cazzamalli, D. Neri, A. Gloger and J. Scheuermann, *Nat. Commun.*, 2025, **16**, 3273; (c) K. Colas, D. Bindl and H. Suga, *Chem. Rev.*, 2024, **124**, 12213; (d) M. L. Merz, S. Habeshian, B. Li, J. G. L. David, A. L. Nielsen, X. Ji, K. Il Khwildy, M. M. Duany Benitez, P. Phothirath and C. Heinis, *Nat. Chem. Biol.*, 2024, **20**, 624; (e) B. D. Ellenbroek, J. P. Kahler, S. R. Evers and S. J. Pomplun, *Angew. Chem., Int. Ed.*, 2024, **63**, e202401704; (f) R. Bucci, L. De Rosa, G. Bertoni, R. Di Stasi, M. della Valle, D. Diana, S. Peppicelli, K. Pegini, M. L. Gelmi, F. Bianchini and L. D. D'Andrea, *Bioorg. Chem.*, 2025, **165**, 109039; (g) D. Di Lorenzo, N. Bisi, R. Bucci, I. Ennen, L. Lo Presti, V. Dodero, R. Brandt, S. Ongeri, M. L. Gelmi and N. Tonali, *iScience*, 2025, **28**, 112272.
- (a) F. M. Paulussen and T. N. Grossmann, *J. Pept. Sci.*, 2023, **29**, e3457; (b) N. M. Grob, C. Remarcik, S. L. Rössler, J. Y. K. Wong, J. C. K. Wang, J. Tao, C. L. Smith, A. Loas, S. L. Buchwald, D. L. Eaton, M. Preciado López and B. L. Pentelute, *ACS Chem. Biol.*, 2024, **19**, 101; (c) E. Oduro-Kwateng, M. Ali, I. O. Kehinde, L. Rao and M. E. S. Soliman, *BMC Methods*, 2025, **2**, 6.
- G. Kim, J. Grams and K. L. Hsu, *Chem. Rev.*, 2025, **125**, 6653.
- (a) C. Gampe and V. A. Verma, *J. Med. Chem.*, 2020, **63**, 14357; (b) M. Mason, L. Belvisi, L. Pignataro and A. Dal Corso, *ChemBioChem*, 2024, **25**, e202300743.
- G. Antonini, A. Bernardi, E. Gillon, A. Dal Corso, M. Civera, L. Belvisi, A. Varrot and S. Mazzotta, *J. Med. Chem.*, 2024, **67**, 19546.



- 6 G. Sacco, D. Arosio, M. Paolillo, A. Gloger, J. Scheuermann, L. Pignataro, L. Belvisi, A. Dal Corso and C. Gennari, *Chem. – Eur. J.*, 2023, **29**, e202203768.
- 7 M. Mason, B. Nava, L. Belvisi, L. Pignataro and A. Dal Corso, *Eur. J. Org. Chem.*, 2024, e202400229.
- 8 M. Meldal and C. Wenzel Tornøe, *Chem. Rev.*, 2008, **108**, 2952.
- 9 A. Dal Corso, M. Catalano, A. Schmid, J. Scheuermann and D. Neri, *Angew. Chem., Int. Ed.*, 2018, **57**, 17178.
- 10 G. Sacco, S. Stammwitz, L. Belvisi, L. Pignataro, A. Dal Corso and C. Gennari, *Eur. J. Org. Chem.*, 2021, 1763–1767.
- 11 (a) G. T. Potter, G. C. Jayson, G. J. Miller and J. M. Gardiner, *J. Org. Chem.*, 2016, **81**, 3443; (b) Y. Zhang, Q. Zhang, C. T. T. Wong and X. Li, *J. Am. Chem. Soc.*, 2019, **141**, 12274–12279.
- 12 C. Delmas, E. Sager, C. Henry, U. Hassiepen, P. R. Skaanderup and I. Kerschgens, *Chimia*, 2025, **79**, 152.
- 13 (a) H. Yu, L. Lin, Z. Zhang, H. Zhang and H. Hu, *Signal Transduction Targeted Ther.*, 2020, **5**, 209; (b) C. A. Rhodes, P. G. Dougherty, J. K. Cooper, Z. Qian, S. Lindert, Q. E. Wang and D. Pei, *J. Am. Chem. Soc.*, 2018, **140**, 12102.
- 14 (a) M. J. May, F. D'Acquisto, L. A. Madge, J. Glöckner, J. S. Pober and S. Ghosh, *Science*, 2000, **289**, 1550; (b) J. S. Orange and M. J. May, *Cell. Mol. Life Sci.*, 2008, **65**, 3564; (c) L. Opazo-Ríos, A. Plaza, Y. er Sánchez Matus, S. Bernal, L. Lopez-Sanz, L. Jimenez-Castilla, D. Carpio, A. Droguett, S. Mezzano, J. Egido and C. Gomez-Guerrero, *Int. J. Mol. Sci.*, 2020, **21**, 4225.
- 15 M. Rushe, L. Silvian, S. Bixler, L. L. Chen, A. Cheung, S. Bowes, H. Cuervo, S. Berkowitz, T. Zheng, K. Guckian, M. Pellegrini and A. Lugovskoy, *Structure*, 2008, **16**, 798.
- 16 (a) K. Peqini, S. Attanasio, L. Fenì, G. Cappelletti and S. Pellegrino, *J. Pept. Sci.*, 2024, **30**, e3556; (b) F. Guzmán, M. Aróstica, T. Román, D. Beltrán, A. Gauna, F. Albericio and C. Cárdenas, *Electron. J. Biotechnol.*, 2023, **64**, 27.
- 17 J. Becerra, *Modulation of NF- $\kappa$ B Activity with Synthetic Inhibitors of NEMO*, PhD thesis, University of Michigan, Ann Arbor, Michigan, USA, 2023.

